QUZYTTIR Drug Patent Profile
✉ Email this page to a colleague
When do Quzyttir patents expire, and what generic alternatives are available?
Quzyttir is a drug marketed by JDP and is included in one NDA. There are five patents protecting this drug.
This drug has five patent family members in five countries.
The generic ingredient in QUZYTTIR is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-eight suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Quzyttir
A generic version of QUZYTTIR was approved as cetirizine hydrochloride by PADAGIS US on June 17th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for QUZYTTIR?
- What are the global sales for QUZYTTIR?
- What is Average Wholesale Price for QUZYTTIR?
Summary for QUZYTTIR
| International Patents: | 5 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 119 |
| Clinical Trials: | 2 |
| Patent Applications: | 2,616 |
| Drug Prices: | Drug price information for QUZYTTIR |
| What excipients (inactive ingredients) are in QUZYTTIR? | QUZYTTIR excipients list |
| DailyMed Link: | QUZYTTIR at DailyMed |
Recent Clinical Trials for QUZYTTIR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| TerSera Therapeutics LLC | Phase 2 |
| JDP Therapeutics, Inc. | Phase 2 |
| TerSera Therapeutics | Phase 2 |
Pharmacology for QUZYTTIR
| Drug Class | Histamine-1 Receptor Antagonist |
| Mechanism of Action | Histamine H1 Receptor Antagonists |
US Patents and Regulatory Information for QUZYTTIR
QUZYTTIR is protected by five US patents.
Patents protecting QUZYTTIR
Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE URTICARIA
Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA
Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA
Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE URTICARIA
Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE URTICARIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for QUZYTTIR
See the table below for patents covering QUZYTTIR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2011003074 | ⤷ Sign Up | |
| Spain | 2616703 | ⤷ Sign Up | |
| Canada | 2803987 | FORMULATIONS POUR INJECTION D'UN ANTIHISTAMINIQUE NON SEDATIF ET LEURS METHODES D'UTILISATION (NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF) | ⤷ Sign Up |
| Australia | 2010266103 | Non-sedating antihistamine injection formulations and methods of use thereof | ⤷ Sign Up |
| European Patent Office | 2477634 | FORMULATIONS POUR INJECTION D'UN ANTIHISTAMINIQUE NON SÉDATIF ET LEURS MÉTHODES D'UTILISATION (NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for QUZYTTIR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0663828 | C300085 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
| 0058146 | 2001C/045 | Belgium | ⤷ Sign Up | PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
